Ju­lian Adams jumps ship from a deeply trou­bled In­fin­i­ty Phar­ma

Ju­lian Adams, the R&D chief of In­fin­i­ty Phar­ma­ceu­ti­cals $IN­FI for the past 14 years and a promi­nent face for one of the most high-pro­file biotechs in Cam­bridge, MA, is out.

Like many such an­nounce­ments, In­fin­i­ty cast the de­par­ture as a re­tire­ment, though it’s un­like­ly that Adams is hang­ing up his lab coat. His last day at In­fin­i­ty is to­mor­row, just days af­ter he qual­i­fied for the first pay­ment of a planned $249,000 re­ten­tion bonus.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER